The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: John Young - Canaccord Genuity - Analyst
: Hi, Jim and Steve. Thanks for taking the question and congrats on a great quarter.
I just want to start first on AngioVac, still remains strong. It was nice to see just despite the very strong quarter you had last quarter, do you think
the $6.8 million is a good new base that we should think about for the business going forward? And I have one follow up. Thanks.
Question: John Young - Canaccord Genuity - Analyst
: Okay, great. Thanks. And then just on that NanoKnife prostate, any further details you could share with us just on your percentage of revenue that's
[attributable to] prostate in the quarter, any KPIs from your direct to consumer, education or physician efforts that you've started with the marketing
approval?
And then for the CPT level 1 code, should we still think of July as being kind of the first update into what the possible reimbursement for next year
looks like? Thanks again for taking our questions.
Question: Steven Lichtman - Oppenheimer & Co. - Analyst
: Thank you. Good morning, guys, and congratulations.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
APRIL 02, 2025 / 12:00PM, ANGO.OQ - Q3 2025 AngioDynamics Inc Earnings Call
Just wanted to also ask on MT, given the strength you're seeing in AngioVac post the AlphaVac launch, can you give us an update on your commercial
efforts across mechanical thrombectomy? I know initially, you're working through where the team focused, obviously, you're seeing success. Are
you looking to further add to the commercial team or are you feeling good about sort of the coverage going after AlphaVac and keeping this
AngioVac momentum going?
Question: Steven Lichtman - Oppenheimer & Co. - Analyst
: Great, thanks. Thanks, Jim. And then just on Auryon, can you give us an update on how things are progressing on the EU launch? And any updated
thoughts on the opportunity there, I guess, a couple of quarters into the [post to see mark].
|
